Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial-Reference-Cited by-同舟云学术

Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial

Published:2020-10 Issue:5 Volume:3 Page:687-694
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Tannir Nizar M.,Msaouel Pavlos,Ross Jeremy A.,Devine Catherine E.,Chandramohan Anuradha,Gonzalez Graciela M. Nogueras,Wang Xuemei,Wang Jennifer,Corn Paul G.,Lim Zita D.,Pruitt Lisa,Karam Jose A.,Wood Christopher G.,Zurita Amado J.

Funder

Novartis

Cancer Center

Publisher

Elsevier BV

Subject

Urology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference17 articles.

1. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma;Atkins;Cancer Treat Rev,2018

2. Clinical practice guidelines in oncology;NCCN;Kidney cancer.,2019

3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol.,2019

4. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med,2007

5. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta-analysis of the risk of adverse cardiovascular events in patients with cancer treated with inhibitors of the PI3K/AKT/mTOR signaling pathway;2024-08-09

2. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway;Journal of Chemotherapy;2023-11-02

3. Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review;European Urology;2023-10

4. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-09-07

5. Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma;Journal of Clinical Medicine;2023-06-07